FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Prognostic model for predicting overall survival in patients with glioblastoma: an analysis based on the SEER database. PMID 36935629 · J Investig Med · 2023-Apr This is a retrospective, non-randomized cohort study using a public database (SEER) to build a prognostic nomogram. It is not a randomized controlled trial, not a Phase III/IIIb or Phase II/III trial, and does not test a specific drug intervention (chemotherapy and radiation are listed as prognostic factors, not as a randomized drug intervention). The primary endpoint is overall survival, but the study design and intervention do not meet the inclusion criteria for a drug-containing randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial. PMID 36932165 · Leukemia · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. PMID 36892745 · Invest New Drugs · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. PMID 36871393 · ESMO Open · 2023-Apr The abstract describes a substudy of the Phase III RAPIDO trial. It is a human oncology randomized trial with drug intervention (chemotherapy) and time-to-event endpoints (DFS, OS). However, the report is a secondary analysis (propensity-score stratified comparison within one arm of the main trial), not the primary randomized result. Therefore, it is eligible as a definitive report with a time-to-event endpoint, but its report type is secondary. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Targeting HER2 in colorectal cancer]. PMID 36870811 · Bull Cancer · 2023-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The challenging imaging and histopathologic features of diffusely infiltrating breast cancer. PMID 36868061 · Eur J Radiol · 2023-Apr The record describes an observational analysis of a breast cancer subtype using data from a past RCT and screening program. It lacks a drug intervention and a primary time-to-event efficacy endpoint, and does not present the primary results of a Phase II/III or III/IIIb randomized trial with a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities. PMID 36867327 · Adv Ther · 2023-Apr 未发现恶性肿瘤人群证据。 |
H
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial. PMID 36827900 · Breast · 2023-Apr The study is an oncology randomized trial with time-to-event endpoints, but it does not include a drug-containing intervention. The primary interventions are radiotherapy fractionation schedules, which are non-drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01). PMID 36807519 · Cancer Med · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. PMID 36804618 · Gynecol Oncol · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications. PMID 36802049 · Adv Ther · 2023-Apr The record reports a pooled safety analysis of baricitinib from randomized trials in rheumatologic and dermatologic diseases. While it involves a drug intervention and randomized data, it is not an oncology trial (malignancy is an adverse event, not the primary disease). Crucially, it lacks a time-to-event efficacy endpoint for a malignant neoplasm, focusing instead on incidence rates of adverse events. Therefore, it does not meet the eligibility criteria for an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial. PMID 36801606 · Eur J Cancer · 2023-Apr The study is an analysis from a Phase III randomized oncology trial with drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, RFS, TTP) using Kaplan-Meier or hazard ratios. It uses logistic regression for a binary outcome (early recurrence), which does not meet the time-to-event criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. PMID 36801605 · Eur J Cancer · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. PMID 36797356 · Br J Cancer · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. PMID 36796234 · Eur J Cancer · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology. PMID 36779385 · J Surg Oncol · 2023-Apr This is a randomized, phase II/III oncology trial with a drug intervention, but the abstract reports only safety outcomes (wound complications). There is no mention of a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, or DFS, nor any reference to Kaplan-Meier estimates or hazard ratios. It is therefore excluded as a safety-only analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. PMID 36774658 · Cancer Treat Rev · 2023-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A prospective randomized controlled study of Mycobacterium Indicus Pranii vaccine, Measles Mumps Rubella vaccine and Vitamin D3 in extragenital cutaneous warts. PMID 36762385 · J Cosmet Dermatol · 2023-Apr 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT). PMID 36737276 · Clin Genitourin Cancer · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. PMID 36717653 · Leukemia · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Temporal association between drops in thoracic impedance and malignant ventricular arrhythmia: A longitudinal analysis of remote monitoring trends. PMID 36709469 · J Cardiovasc Electrophysiol · 2023-Apr The study is not about human malignant neoplasms (oncology). It is a cardiology study analyzing thoracic impedance from implantable cardioverter-defibrillators to predict ventricular arrhythmias. Therefore, it fails the primary oncology criterion. Even if it were oncology, it lacks a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. PMID 36706958 · Radiother Oncol · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Improving emotion regulation in breast cancer patients in the early survivorship period: Efficacy of a brief ecologically boosted group intervention. PMID 36703250 · Psychooncology · 2023-Apr The study is a randomized trial in breast cancer patients evaluating a psychological intervention (emotion regulation group therapy) for psychological symptoms. It does not involve a drug-containing intervention and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier analysis). Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Intraoperative Radiotherapy in the Treatment of Recurrent High-Grade Glioma: A Single-Center Prospective Study. PMID 36682529 · World Neurosurg · 2023-Apr The study is a randomized trial with a primary time-to-event efficacy endpoint (PFS, OS) for a human malignant neoplasm (high-grade glioma), but it evaluates a non-drug intervention (intraoperative radiotherapy) and does not report Phase III/IIIb or Phase II/III evidence. It is excluded because it lacks a drug-containing intervention and definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. PMID 36681299 · Ann Oncol · 2023-Apr The record describes a randomized trial with drug intervention and time-to-event efficacy endpoints (OS, RFS), and is an updated survival analysis. However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata; the title and abstract do not specify the trial phase, making eligibility indeterminate. Confidence is moderate due to clear oncology, human, randomized, drug, and endpoint criteria, but phase is unclear. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prognosis of Patients With Triple-negative Breast Cancer: A Population-based Study From SEER Database. PMID 36669957 · Clin Breast Cancer · 2023-Apr The study is an oncological analysis of human patients with a time-to-event endpoint (cancer-specific survival). However, it is excluded because it is not a randomized controlled trial (it is a retrospective, population-based study using SEER data), lacks a drug-containing intervention (focuses on surgery and prognostic factors), and is not a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel cardiac arrest severity score for the early prediction of hypoxic-ischemic brain injury and in-hospital death. PMID 36669440 · Am J Emerg Med · 2023-Apr The study is a retrospective analysis and validation of a novel cardiac arrest severity score, not a randomized trial of a drug intervention in oncology. It does not report Kaplan-Meier survival analyses or hazard ratios for a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. PMID 36653664 · Ann Surg Oncol · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). PMID 36598575 · J Neurol · 2023-Apr 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exercise adherence in a randomized controlled trial of exercise on quality of life in ovarian cancer survivors. PMID 36550261 · J Cancer Surviv · 2023-Apr This is an original result report of a randomized controlled trial in human ovarian cancer survivors. However, it does not meet the eligibility criteria because (1) the intervention is a non-drug telephone-based exercise counseling program, with no drug-containing intervention; (2) the primary endpoint is exercise adherence, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.; and (3) the phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility, Safety, and Functional Outcomes of Pelvic Hypothermia Induced Using a Rectal Cooling Device During Robot-Assisted Radical Prostatectomy: A Phase I/II Trial. PMID 36534766 · J Endourol · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE). PMID 36515003 · Cancer Med · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of esophageal submucosal tumors treated with internal traction method-assisted submucosal tunneling endoscopic resection: a single-center, single-blind, randomized controlled study. PMID 36509948 · Surg Endosc · 2023-Apr Study is a randomized controlled trial of a surgical/endoscopic procedure for esophageal submucosal tumors, with no drug intervention and no primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The efficacy outcomes are procedural (resection rates, complications, recovery metrics). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. PMID 36494496 · Esophagus · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer. PMID 36484758 · J Clin Pharmacol · 2023-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Recurrence patterns after curative gastrectomy for pStage II/III gastric cancer: Exploratory analysis of the randomized controlled JCOG1001 trial. PMID 36424261 · Eur J Surg Oncol · 2023-Apr While the record describes a randomized oncology trial with original results, it lacks two key eligibility criteria: 1) a drug-containing intervention (the trial appears to compare surgical techniques), and 2) a primary/key secondary time-to-event efficacy endpoint (the analysis is on recurrence patterns and risk factors, not OS/PFS/etc. with Kaplan-Meier or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis. PMID 36402643 · Clin Genitourin Cancer · 2023-Apr The study is a retrospective multi-institutional database analysis, not a randomized trial. Although publication types include 'Randomized Controlled Trial', the methods clearly state it is a retrospective observational study using a database query. There is no evidence of a randomized intervention, no defined trial phase (Phase III/IIIb or Phase II/III), and it is not a prospective randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol design for randomized clinical trial to compare underwater cold snare polypectomy to conventional cold snare polypectomy for non-pedunculated colon polyps of size 5-10 mm (COLDWATER study). PMID 36399201 · Tech Coloproctol · 2023-Apr The record is a clinical trial protocol for a comparison of endoscopic techniques (polypectomy methods), not a drug intervention. It is a protocol without results, and the primary endpoint is a histological resection rate, not a time-to-event efficacy endpoint. Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA-2 trial. PMID 36345809 · Pharmacoepidemiol Drug Saf · 2023-Apr The record describes an observational study emulating a randomized trial (PALOMA-2), not the original report of a randomized Phase III/IIIb trial. It is not randomized, not an original trial result, and not a Phase III trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial. PMID 36328489 · J Nucl Med · 2023-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and prognostic value of delta radiomics on dual-energy computed tomography for gastric cancer with neoadjuvant chemotherapy: a preliminary study. PMID 36062762 · Acta Radiol · 2023-Apr The study is an oncology randomized trial with a drug intervention (neoadjuvant chemotherapy) and a time-to-event endpoint (survival). However, it is a Phase II or earlier exploratory/prognostic radiomics study; it is not a Phase III/IIIb or Phase II/III randomized trial as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Computed Tomography-based Radiomics Evaluation of Postoperative Local Recurrence of Pancreatic Ductal Adenocarcinoma. PMID 35906151 · Acad Radiol · 2023-Apr The study is a diagnostic radiomics model validation for postoperative recurrence detection in pancreatic cancer. It is randomized (for cohort splitting) but lacks a drug-containing intervention and reports diagnostic performance (AUC) rather than a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-cell lymphoma. PMID 35754170 · Asia Pac J Clin Oncol · 2023-Apr The study is a randomized retrospective prognostic analysis in oncology patients with a time-to-event endpoint, but it does not report a drug-containing intervention trial (no intervention arm is described) and the trial phase (Phase III/IIIb or II/III) is not established in the metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| De-Novo Depression, Prophylactic Antidepressant, and Survival in Patients With Head and Neck Cancer. PMID 35730719 · Laryngoscope · 2023-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A cost analysis of sorafenib for desmoid tumors. PMID 35112974 · J Oncol Pharm Pract · 2023-Apr The record is a cost analysis of a randomized trial, which is an economic analysis and not eligible as an original formal-result report of efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. PMID 37921681 · Am J Ther · 2023 Nov The record describes a randomized, Phase 3 trial of a drug for psoriasis, but it is not an oncology study, and the primary efficacy endpoint is not a time-to-event measure (e.g., OS, PFS, KM). |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Social Determinants of Health and Symptom Burden During Cancer Treatment. PMID 36729777 · Nurs Res · 2023 Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Features. PMID 37380154 · J Comput Assist Tomogr · 2023 Jul The study is a retrospective biomarker/prognostic analysis in oncology patients but does not involve a drug-containing intervention (the 'Randomized Controlled Trial' publication type tag appears erroneous for this study design), and there is no evidence of a Phase III/IIIb or Phase II/III randomized trial. It is therefore excluded per the criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Analysis of Survival Quality of Peroneal Artery Perforator Flap in Immediate Repairment and Reconstruction of Oral and Maxillofacial Malignancies. PMID 37185316 · J Craniofac Surg · 2023 Jul The study is a randomized trial in oncology (oral and maxillofacial malignant tumors) but is ineligible because it does not involve a drug-containing intervention (it compares surgical flap reconstruction techniques) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.); the outcomes are postoperative quality-of-life and functional scores. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic Value of the Radiomics-Based Model in the Disease-Free Survival of Pretreatment Uveal Melanoma: An Initial Result. PMID 36668984 · J Comput Assist Tomogr · 2023 Jan The study is a randomized trial analyzing disease-free survival (DFS) in uveal melanoma patients, but it does not involve a drug-containing intervention. The randomization is used to split the cohort into training/validation sets for model building, not to compare therapeutic arms. The phase is not explicitly stated as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |